Pharma Focus Europe

Medison Pharma and Alnylam Pharmaceuticals Expand Collaboration to Introduce RNAi Therapeutics in Additional LATAM and APAC Territories, Including Australia

Wednesday, May 01, 2024

Medison Pharma ("Medison") and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) have announced an expansion of their partnership to include selected markets in Latin America (LATAM) and the Asia-Pacific (APAC) regions, along with additional international markets. Medison specializes in providing innovative therapies for rare and severe diseases, while Alnylam is a leader in RNAi therapeutics.

The collaboration between the two companies began in 2018 and has since grown to include more regions and markets. This expansion aims to ensure broader access to Alnylam's key therapies such as ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran) across diverse international territories.

Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam, expressed enthusiasm about the expanded partnership, emphasizing the opportunity to reach more patients globally with innovative RNAi therapeutics.

Medison, highlighted the significance of multi-regional partnerships in facilitating access to advanced biotech treatments, underscoring their commitment to bridging geographical divides to benefit patients worldwide.

Medison, emphasized the value of their unified commercial platform in streamlining access to diverse markets, citing the partnership with Alnylam as a testament to its effectiveness in expanding patient access to life-saving therapies.

RNA interference (RNAi) is hailed as a groundbreaking biological process with the potential to revolutionize medicine. Alnylam's RNAi therapeutics leverage this natural mechanism to silence disease-causing genes, offering a promising approach to treating genetic and other diseases.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024